Modality
mAb
MOA
AuroraAi
Target
AHR
Pathway
Ferroptosis
GBMPNH
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
Sep 2018
→ Jan 2030
Phase 2Current
NCT06348140
1,377 pts·PNH
2024-04→TBD·Not yet recruiting
NCT08562823
2,535 pts·GBM
2018-09→2030-01·Completed
3,912 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-023.8y awayPh2 Data· GBM
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2
Complet…
P2
Not yet…
Catalysts
Ph2 Data
2030-01-02 · 3.8y away
GBM
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06348140 | Phase 2 | PNH | Not yet recr... | 1377 | Safety |
| NCT08562823 | Phase 2 | GBM | Completed | 2535 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |